Fraiser Kansteiner is a contributing writer for Fierce Pharma. With a focus on topics such as manufacturing, drug delivery, and COVID-19, Fraiser provides insightful coverage of the pharmaceutical industry. His articles offer in-depth analysis and reporting on the latest developments and trends within the sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Fraiser Kansteiner's coverage primarily revolves around the healthcare and pharmaceutical industry, with a focus on regulatory announcements, press releases, and data citations. To effectively reach out to Fraiser, consider providing insights into pharmaceutical industry trends, drug developments or FDA regulations. Sources with access to unpublished data or exclusive information about pivotal events within the healthcare sector may be of particular interest to him.
Since Fraiser does not specify any geographic focus in his articles, it is likely that he covers global pharmaceutical news and would be interested in international perspectives on key issues within the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Fraiser Kansteiner
With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France's Orano Med is doubling down on the nuclear medicine craze.
By: Fraiser Kansteiner
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai's serotonin 2C receptor agonist lorcaserin.
By: Fraiser Kansteiner
A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli Lilly is turning up the heat on the drugmakers' potential lipoprotein showdown.
By: Fraiser Kansteiner
Although AstraZeneca, Daiichi Sankyo and England's drug cost watchdog have spent months trying to hash out a fair price for Enhertu, the trio's best
By: Fraiser Kansteiner
After a labeling mix-up prompted a recall of a popular panic disorder drug this summer, Endo's U.S. subsidiary is widening the scope of its product pull.
By: Fraiser Kansteiner
As a council of outside experts prepares to meet Thursday to discuss AstraZeneca's Andexxa, the FDA has flagged “major safety findings” linked to the British drugmaker's bleeding reversal agent.
By: Fraiser Kansteiner
With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it's likely back to the drawing board for Canadian private equity outfit Brookfield.
By: Fraiser Kansteiner
On the back several strong quarters and a year already chock full of manufacturing accords, Korean CDMO Samsung Biologics is adding yet another project to its contract manufacturing rolodex.
By: Fraiser Kansteiner
As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the returning administration's
By: Fraiser Kansteiner
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the country. But that's not discouraging Pfizer.
(833) 317-6278 
